Avanos Medical (NYSE:AVNS) Upgraded at Zacks Research

Zacks Research upgraded shares of Avanos Medical (NYSE:AVNS) from a strong sell rating to a hold rating in a research report sent to investors on Monday morning,Zacks.com reports.

Several other analysts have also recently weighed in on AVNS. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Avanos Medical Price Performance

AVNS opened at $12.88 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. The stock has a market capitalization of $597.70 million, a P/E ratio of -1.26 and a beta of 1.08. The company’s 50 day simple moving average is $11.82 and its 200-day simple moving average is $11.64. Avanos Medical has a one year low of $9.30 and a one year high of $17.69.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.10. The firm had revenue of $177.80 million during the quarter, compared to analysts’ expectations of $164.50 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. Avanos Medical’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.33 EPS. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Sell-side analysts anticipate that Avanos Medical will post 1.32 earnings per share for the current fiscal year.

Insider Activity at Avanos Medical

In related news, SVP Kerr Holbrook sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total value of $165,000.00. Following the sale, the senior vice president directly owned 83,860 shares in the company, valued at $922,460. This trade represents a 15.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.64% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Armistice Capital LLC boosted its position in shares of Avanos Medical by 22.8% during the third quarter. Armistice Capital LLC now owns 2,500,000 shares of the company’s stock worth $28,900,000 after purchasing an additional 464,000 shares in the last quarter. Millennium Management LLC raised its stake in Avanos Medical by 312.4% during the 3rd quarter. Millennium Management LLC now owns 896,242 shares of the company’s stock worth $10,361,000 after buying an additional 678,898 shares during the period. Tributary Capital Management LLC raised its stake in Avanos Medical by 10.0% during the 2nd quarter. Tributary Capital Management LLC now owns 810,720 shares of the company’s stock worth $9,923,000 after buying an additional 73,518 shares during the period. Clark Estates Inc. NY lifted its holdings in Avanos Medical by 58.7% during the third quarter. Clark Estates Inc. NY now owns 783,880 shares of the company’s stock worth $9,062,000 after acquiring an additional 290,000 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its stake in Avanos Medical by 16.4% in the third quarter. Qube Research & Technologies Ltd now owns 727,838 shares of the company’s stock valued at $8,414,000 after acquiring an additional 102,429 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.